The executive order, which Biden signed in October 2022, had not spurred any lower drug prices by the time Trump revoked it Jan. 20. The order directed the Health and Human Services Department secretary to consider "new health care payment and delivery models" for the Center for Medicare and Medicaid Innovation to test.

Early moves by the president raise questions about what direction his second-term policy on drug costs will take.